News & Events / Events / Webinar
Inside PRMT5: Metabolomics-Driven Insights for Cancer Therapy
PRMT5 is a promising therapeutic target, especially in MTAP-deleted tumors, but measuring its inhibition has remained a challenge. In this webinar, Panome Bio scientists introduce a targeted metabolite assay that delivers precise, quantitative insights into PRMT5 activity.
By profiling key metabolites — SAM, MTA, SDMA, and ADMA — this approach reveals metabolic patterns linked to PRMT isoform activity, MTAP deletion, and tumor-specific responses.
Discover how targeted metabolomics enables more accurate evaluation of PRMT5 therapies, supports biomarker discovery, and drives translational breakthroughs in oncology in this webinar.
PRESENTED BY:
Ethan Stancliffe, PhD
Dr. Stancliffe is the Senior Director of R&D at Panome Bio. He completed his PhD work in Computational and Systems Biology at Washington University in St. Louis with research focused on computational methods for the analysis and processing of untargeted metabolomics data. Dr. Stancliffe also holds a BS in Biomedical Engineering and Applied Mathematics from the University of Iowa.
Watch now
Your privacy is important to us.
We’ll never share your information.